Medtronic to Report Fiscal Fourth Quarter Results; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Medtronic (MDT) to report Q4 2026 results on 6/3, expected revenue of $9.61B & EPS of $1.55. Recent acquisition of SPR Therapeutics adds to neuromodulation business. Analyst ratings show mixed opinions. Latest Ratings for MDT Date Firm Action From To Feb 2022 Credit Suisse Maintains Outperform Feb 2022 Needham Maintains Buy Feb 2022 Raymond James Maintains Outperform View More Analyst Ratings for MDT View the Latest Analyst Ratings Importance Rank: 1 read more

Go to News Site